WO2015072247A1 - Composition de médicament de ciblage de cellule souche cancéreuse - Google Patents

Composition de médicament de ciblage de cellule souche cancéreuse Download PDF

Info

Publication number
WO2015072247A1
WO2015072247A1 PCT/JP2014/076841 JP2014076841W WO2015072247A1 WO 2015072247 A1 WO2015072247 A1 WO 2015072247A1 JP 2014076841 W JP2014076841 W JP 2014076841W WO 2015072247 A1 WO2015072247 A1 WO 2015072247A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer stem
stem cell
cancer
eribulin
group
Prior art date
Application number
PCT/JP2014/076841
Other languages
English (en)
Japanese (ja)
Inventor
健吉 増富
麻美 安川
聡子 山口
Original Assignee
独立行政法人国立がん研究センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2013236252A external-priority patent/JP2017036213A/ja
Priority claimed from JP2013272637A external-priority patent/JP2017036216A/ja
Application filed by 独立行政法人国立がん研究センター filed Critical 独立行政法人国立がん研究センター
Publication of WO2015072247A1 publication Critical patent/WO2015072247A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)

Abstract

La présente invention vise à fournir un médicament qui cible une cellule souche cancéreuse et qui peut ainsi prévenir une récidive et des métastases de façon à guérir entièrement un cancer. L'invention concerne une composition de médicament de ciblage de cellule souche cancéreuse et analogue, ladite composition de médicament de ciblage de cellule souche cancéreuse comprenant un composé choisi parmi le groupe constitué de VX-222, d'éribuline, de vindésine, de β-rubromycine, de BIBR1532, de dérivés de ces derniers et de sels et solvates pharmacologiquement acceptables de ces derniers.
PCT/JP2014/076841 2013-11-14 2014-10-07 Composition de médicament de ciblage de cellule souche cancéreuse WO2015072247A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2013236252A JP2017036213A (ja) 2013-11-14 2013-11-14 がん幹細胞標的薬組成物
JP2013-236252 2013-11-14
JP2013-272637 2013-12-27
JP2013272637A JP2017036216A (ja) 2013-12-27 2013-12-27 がん幹細胞標的薬組成物

Publications (1)

Publication Number Publication Date
WO2015072247A1 true WO2015072247A1 (fr) 2015-05-21

Family

ID=53057190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/076841 WO2015072247A1 (fr) 2013-11-14 2014-10-07 Composition de médicament de ciblage de cellule souche cancéreuse

Country Status (1)

Country Link
WO (1) WO2015072247A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113832226A (zh) * 2020-06-24 2021-12-24 广州医科大学附属第五医院 研究gnl3与肝癌发展的相关性的方法及gnl3作为肝肿瘤干细胞、肝癌标志物的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063135A2 (fr) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Criblage d'isotype de tubuline en therapie du cancer, au moyen d'analogues d'hemiasterline

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063135A2 (fr) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Criblage d'isotype de tubuline en therapie du cancer, au moyen d'analogues d'hemiasterline

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DONG HOON SU H ET AL.: "Major clinical research advances in gynecologic cancer in 2011", JOURNAL OF GYNECOLOGIC ONCOLOGY, vol. 23, no. 1, 22 December 2011 (2011-12-22), pages 53 - 64 *
EMANUELLE PASCOLO ET AL.: "Mechanism of Human Telomerase Inhibition by BIBR1532, a Synthetic, Non-nucleosidic Drug Candidate", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 18, 19 February 2002 (2002-02-19), pages 15566 - 15572 *
GUANGHUI YI ET AL.: "Biochemical Study of the Comparative Inhibition of Hepatitis C Virus RNA Polymerase by VX-222 and Filibuvir", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 5, no. 2, February 2012 (2012-02-01), pages 830 - 837 *
KEITA KINOSHITA ET AL.: "New functions of telomerase", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 241, no. 11, 16 June 2012 (2012-06-16), pages 841 - 845 *
KEITA KINOSHITA ET AL.: "Telomerase: Telomere Shincho Hanno to Arata na Kino", KAGAKU TO SEIBUTSU, vol. 48, no. 11, 2010, pages 780 - 784 *
KLAUS DAMM ET AL.: "A highly selective telomerase inhibitor limiting human cancer cell proliferation", THE EMBO JOURNAL, vol. 20, no. 24, 26 October 2001 (2001-10-26), pages 6958 - 6968 *
NAOKO OKAMOTO ET AL.: "3. Telomerase o Hyoteki to shite Gan Kansaibo Hyoteki Chiryo no Kanosei", EXPERIMENTAL MEDICINE, vol. 29, no. 20, 2011, pages 197 - 202 *
TAKAMASA UENO ET AL.: "Inhibition of Human Telomerase by Rubromycins; Implication of Spiroketal System of the Compounds as an Active Moiety", BIOCHEMISTRY, vol. 39, 16 May 2000 (2000-05-16), pages 5995 - 6002 *
YOSHIKO MAIDA ET AL.: "An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA", NATURE, vol. 461, pages 230 - 237 *
YOSHIKO MAIDA ET AL.: "Kakudai suru Telomerase no Biology", EXPERIMENTAL MEDICINE, vol. 31, no. 9, June 2013 (2013-06-01), pages 14 21 - 1426 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113832226A (zh) * 2020-06-24 2021-12-24 广州医科大学附属第五医院 研究gnl3与肝癌发展的相关性的方法及gnl3作为肝肿瘤干细胞、肝癌标志物的用途
CN113832226B (zh) * 2020-06-24 2023-06-30 广州医科大学附属第五医院 研究gnl3与肝癌发展的相关性的方法及gnl3作为肝肿瘤干细胞、肝癌标志物的用途

Similar Documents

Publication Publication Date Title
Cui et al. Small nucleolar noncoding RNA SNORA23, up-regulated in human pancreatic ductal adenocarcinoma, regulates expression of spectrin repeat-containing nuclear envelope 2 to promote growth and metastasis of xenograft tumors in mice
EP4085919A2 (fr) Compositions et procédés permettant de traiter un cancer
JP2018507866A (ja) マイクロｒｎａを有効成分として含む癌治療用医薬組成物
JP2022050493A (ja) 癌を治療する方法における使用のための毛細血管拡張性運動失調症の変異したＲａｄ３関連タンパク質キナーゼ（ＡＴＲ）の阻害剤
US11584932B2 (en) 5-halouracil-modified microRNAs and their use in the treatment of cancer
TW200812590A (en) Methods for cancer therapy and stem cell modulation
JP5933010B2 (ja) 癌治療剤
US11236337B2 (en) 5-halouracil-modified microRNAs and their use in the treatment of cancer
US10697020B2 (en) MicroRNA-129 as a biomarker for colorectal cancer
EP2760457A1 (fr) Procédés et compositions pharmaceutiques pour le traitement du cancer
JP5812491B2 (ja) 腫瘍治療剤
WO2015072247A1 (fr) Composition de médicament de ciblage de cellule souche cancéreuse
JP2022506958A (ja) Ｍｉｒ－１０ｂ活性を調節するためのマイクロｒｎａ化合物及び方法
US20220090076A1 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
US20210277395A1 (en) Methods and compositions for modulating lncrnas and methods of treatment based on lncrna expression
JP2017036213A (ja) がん幹細胞標的薬組成物
CA3058927A1 (fr) Composes imidopiperidines en tant qu'inhibiteurs de la polynucleotide phosphatase kinase humaine
JP2023515010A (ja) 免疫原性細胞死を促進するためのｍｉＲＮＡ－１９３ａ
JP2017036216A (ja) がん幹細胞標的薬組成物
WO2010050328A1 (fr) Inhibiteur de métastase de tumeur
CN118043053A (en) Methods of treating cancer
Calonego Combining antisense drugs targeting thymidylate synthase and indoleamine 2, 3-dioxygenase in human cancer cells: potentialfor combined therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14862368

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14862368

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP